Kbtbd13 knockdown restores muscle function in a clinically relevant mouse model of nemaline myopathy type 6
Authors:
- Ricardo A. GalliRGRicardo A. Galli
- Leander A. VonkLVLeander A. Vonk
- Rianne J. BaeldeRBRianne J. Baelde
- Anita van Den HeuvelAHAnita van Den Heuvel
- Sylvia BogaardsSBSylvia Bogaards
- Stefan ConijnSCStefan Conijn
- Emma SiteurESEmma Siteur
- Olga AlekhinaOAOlga Alekhina
- Henk GranzierHGHenk Granzier
- Thomas IrvingThomas Irving
- Weikang MaWeikang Ma
- Karlijn BoumanKBKarlijn Bouman
- 24 June 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (855) , eadx2116
Abstract
Nemaline myopathy type 6 (NEM6) is a rare neuromuscular disorder caused by pathogenic variants in the Kelch repeat and BTB domain–containing 13 ( KBTBD13 ) gene. Patients experience muscle weakness, excessive fatigue, and impaired muscle relaxation that affect their daily activities related to abnormal protein aggregation in muscle cells and a predominance of slow-twitch myofibers, and no specific therapies are available. Here, we studied a clinically relevant Kbtbd13 :p.Arg408Cys knockin mouse model to elucidate the molecular changes driving disease pathogenesis through measurements of muscle contractility, single myofiber assays, super-resolution microscopy, and x-ray diffraction. Kbtbd13 :p.Arg408Cys knockin mice closely phenocopied human NEM6 pathology at the morphological, functional, and transcriptional levels, with the p.Arg408Cys variant causing mislocalization of KBTBD13 in the muscle sarcomere, associated with disease onset between 1 and 3 months of age, plateauing by 9 months, and with little progression at 18 months. As a potential therapeutic approach, we knocked down Kbtbd13 using short hairpin RNA against Kbtbd13 delivered intramuscularly via an adeno-associated virus 9 vector at either the prephenotype (1-month-old) or peak-phenotype (3- or 7-month-old) stages. A single treatment at the prephenotype stage prevented the development of impaired relaxation kinetics, nemaline rod aggregation, and slow-twitch myofiber predominance at 3 months of age. A single treatment at 3 months of age, after onset of disease, restored muscle morphology, contractility, and muscle-relaxation kinetics over 6 months. These data provide insights into NEM6 pathogenesis and suggest that Kbtbd13 knockdown might be a promising therapeutic strategy for patients with NEM6.Keywords
Funding Information
- National Institutes of Health (P30 GM138395)
- ZonMW-VICI (91819613)
- Princess Beatrix Fund (W.OR23-06)
- ZonMW-VENI (09150161910168)
This publication has 90 references indexed in Scilit:
- KBTBD13 is a novel cardiomyopathy geneHuman Mutation, 2022
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Clinico-pathological features and mutational spectrum of 16 nemaline myopathy patients from a Chinese neuromuscular centerActa Neurologica Belgica, 2021
- Nemaline myopathy and distal arthrogryposis associated with an autosomal recessive TNNT3 splice variantHuman Mutation, 2018
- Nemaline myopathy type 6: Clinical and myopathological featuresMuscle & Nerve, 2010
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Nemaline myopathy: A clinical study of 143 casesAnnals of Neurology, 2001
- Changes in thick filament structure during compression of the filament lattice in relaxed frog sartorius muscleJournal of Muscle Research and Cell Motility, 1989
- Genetics of congenital nemaline myopathyMuscle & Nerve, 1980
- Nemaline myopathy: Histological, histochemical and ultrastructural studiesActa Neuropathologica, 1978